Bristol Myers Squibb stock at USD 63.88 on September 28, 2026
Published on 09/28/2026 at 22:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Trading session
Bristol Myers Squibb stock was last traded at USD 63.88 on the New York Stock Exchange on September 28, 2026, at 20:00:02 UTC. The share was up USD 1.02, or 1.62 percent, from the prior session’s USD 62.86 close.
Phase 3 multiple myeloma data
On September 25, 2026, Bristol Myers Squibb announced the first presentation of results from the Phase 3 EXCALIBER-RRMM trial evaluating ZENBEXUS, or iberdomide, with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma. In 420 evaluable patients, the minimal residual disease-negative complete response rate was 41.10 percent with the ZENBEXUS combination, compared with 20.70 percent for daratumumab, bortezomib and dexamethasone. The median follow-up was 15.70 months. The company said the results were presented at the 2026 International Myeloma Society meeting and simultaneously published in The Lancet Oncology. Bristol Myers Squibb
Quarterly dividend declared
On September 16, 2026, Bristol Myers Squibb said its board declared a quarterly dividend of USD 0.63 per share. The dividend is payable on November 2, 2026, to stockholders of record at the close of business on October 2, 2026. Bristol Myers Squibb
